The Market Reports

Synopsis

The global market for Peanut Allergy Therapeutics was estimated to be worth US$ 752 million in 2024 and is forecast to a readjusted size of US$ 1595 million by 2031 with a CAGR of 11.4% during the forecast period 2025-2031.

Peanut Allergy Therapeutics refer to a range of preventive and treatment approaches designed to address the immune system’s abnormal response triggered by peanut proteins. These therapies include oral immunotherapy (OIT), subcutaneous immunotherapy, and emerging biologics and small molecule drugs, aiming to increase patients’ tolerance to peanuts and reduce the frequency and severity of allergic reactions. As one of the most common and potentially life-threatening food allergies globally affecting both children and adults, peanut allergy significantly impacts patient quality of life and imposes economic burdens on society. With advancements in precision medicine and immune modulation technologies, peanut allergy treatment is evolving from mere avoidance strategies to active immune regulation, driving rapid growth in clinical practice and market demand.

In recent years, rising global awareness of food safety and the expanding population of peanut allergy patients have created significant growth opportunities for the peanut allergy therapeutics market. Governments and regulatory bodies worldwide have progressively improved support policies, facilitating clinical approval and market introduction of immunotherapies and innovative biologics. Advances in medical technologies have enhanced the maturity of oral immunotherapy and personalized treatment regimens, markedly improving patient compliance and safety, thereby accelerating market demand. Multiple biopharmaceutical companies have increased R&D investments, actively developing differentiated products and combination therapies, contributing to a diversified and high-value competitive landscape.Despite vast market potential, the peanut allergy therapeutics sector faces several challenges. Allergic reactions and safety concerns during treatment limit patient acceptance and slow adoption rates. Uneven distribution of medical resources across regions affects treatment accessibility and coverage. Additionally, the high costs and complex management of therapies pose challenges for reimbursement systems and patient affordability. The lack of standardized treatment protocols and regulatory discrepancies further complicate cross-border product launches.

Companies must carefully balance innovation breakthroughs with risk management to ensure stable market growth.Downstream demand for peanut allergy therapeutics is moving toward precision and comprehensive care management. With broader adoption of early screening technologies and increased public awareness, more potential patients will receive timely diagnosis and intervention, fostering wider use of immunotherapies. Collaboration among primary care physicians, allergy specialists, and school health programs will strengthen, promoting personalized and long-term treatment management. There is growing demand for safer, more convenient products, while digital health solutions and telemedicine support will become vital tools to enhance adherence and monitor treatment efficacy.

Overall, the market is evolving into an integrated ecosystem encompassing diagnosis, therapy, and follow-up care.

This report aims to provide a comprehensive presentation of the global market for Peanut Allergy Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peanut Allergy Therapeutics by region & country, by Type, and by Distribution Channel.

The Peanut Allergy Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peanut Allergy Therapeutics.

Market Segmentation
By Company

• Viatris
• Bayer
• UCB Pharma
• J & J
• Perrigo
• GSK
• Kaleo
• Amneal Pharma
• ALK Abello
• Aimmune Therapeutics
• HUAPONT Pharm
• Allergy Therapeutics
• ASIT Biotech
• Sanofi
• DBV Technologies
• HAL Allergy
• Intrommune Therapeutics

Segment by Type

• Epinephrine Injection
• Antihistamines
• Oral Immunotherapy
• Other

Segment by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.